Table 6.
Frequency of Melan-A/Mart-127–35–specific CTL Effectors in Day 28 Bulk Cultures after T Cell Activation with Peptide-loaded T2 Cells: Comparison of LDA and T Cell Staining with Melan-A/Mart-1–HLA-A*0201 Tetrameric Complexes
| Patient | Evaluation by LDA | Evaluation by HLA-A*0201– Melan-A/Mart-126–35 tetrameric complexes | ||
|---|---|---|---|---|
| Peptide-specific CTL effector frequency after lymphocyte activation with | HLA-A2–restricted CTL effector frequency after lymphocyte activation with peptide-loaded T2 cells | |||
| Peptide-specific effector frequency after lymphocyte activation with peptide-loaded T2 cells | ||||
| Peptide-loaded T2 | Empty T2 | |||
| 1 | 1/9.8 | <1/200,000 | ND | 1/10.3 |
| 2 | 1/15.8 | ND | 1/14.2 | 1/10.4 |
| 6 | 1/24 | ND | 1/42 | 1/23.1 |
| 3 | 1/4,531 | ND | ND | ND |
| 4 | 1/576 | <1/200,000 | ND | ND |
| 5 | 1/1,093 | <1/200,000 | ND | 1/961 |
| 7 | 1/1,509 | <1/200,000 | ND | ND |
| 8 | 1/831 | <1/200,000 | ND | 1/685 |
Patients' PBLs were cultured for 28 d in bulk culture in the presence of T2 cells either empty or loaded with Melan-A/Mart-127–35 peptide.
Frequency of peptide-specific CTL effectors in bulk cultures was evaluated by LDA or by HLA-A*0201–Melan-A/Mart-1 tetramer staining.